Cargando…

Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Urologia 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442146/ https://www.ncbi.nlm.nih.gov/pubmed/30860337 http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0734

Ejemplares similares

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
por: Mahase, Sean, et al.
Publicado: (2020)

Radiotherapy Treatment Planning in the Age of AI: Are We Ready Yet?
por: Zheng, Dandan, et al.
Publicado: (2019)

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Systems Cytogenomics: Are We Ready Yet?
por: Iourov, Ivan Y., et al.
Publicado: (2021)

Are we there yet?
por: McCann, Shaun R.
Publicado: (2022)

Hypofractionation trials and radiobiology of prostate cancer
por: Gulliford, Sarah, et al.
Publicado: (2017)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Diagnostic digital cytopathology: Are we ready yet?
por: House, Jarret C., et al.
Publicado: (2013)

Evolution of ACO readiness to optimize medication use: are we there yet?
por: Westrich, Kimberly, et al.
Publicado: (2020)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer
por: Tovanabutra, Chokaew, et al.
Publicado: (2020)

Regenerative medicine: are we there yet?
por: Badylak, Stephen, et al.
Publicado: (2017)

Precision Oncology: Are We There Yet?
Publicado: (2017)

Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment
por: Viani, Gustavo Arruda, et al.
Publicado: (2013)

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
por: Oehler, Christoph, et al.
Publicado: (2022)

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation
por: Cante, Domenico, et al.
Publicado: (2020)

Prostate cancer and hypofractionation: really a new standard of care?
por: Carrie, Christian, et al.
Publicado: (2016)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
por: Musunuru, Hima Bindu, et al.
Publicado: (2014)

Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa
por: Swanson, William, et al.
Publicado: (2021)

Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey
por: Sabbagh, Ali, et al.
Publicado: (2023)

Personalized medicine for asthma: Are we there yet?
por: Poon, Audrey H., et al.
Publicado: (2012)

Biomarkers in Alzheimer disease: are we there yet?
por: Generoso, Jaqueline S., et al.
Publicado: (2020)

The COVID‐19 world – Are we there yet?
por: Hamamoto, Yoshiyuki
Publicado: (2021)

Value of Information Analysis: Are We There Yet?
por: Tuffaha, Haitham
Publicado: (2020)

A Comparative Study of Hypofractionated and Conventional Radiotherapy in Postmastectomy Breast Cancer Patients
por: Rastogi, Kartick, et al.
Publicado: (2018)

Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial
por: Mendez, Lucas C., et al.
Publicado: (2020)

Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy
por: Lausch, Anthony, et al.
Publicado: (2017)

Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
por: Guo, Wei, et al.
Publicado: (2019)

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B
por: Juarez, Jesus E., et al.
Publicado: (2020)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
por: Ray, K.J., et al.
Publicado: (2015)

Image-Guided Hypofractionated Radiotherapy in Low-Risk Prostate Cancer Patients
por: Valeriani, Maurizio, et al.
Publicado: (2014)

Pandemic influenza preparedness in the WHO African region: are we ready yet?
por: Sambala, Evanson Z., et al.
Publicado: (2018)

Is fMRI Ready to Replace IAP? Wait, Wait,…We Are Not There Yet!
por: Szaflarski, Jerzy P.
Publicado: (2020)

Are We Ready for Anything?
por: Neal-Boylan, Leslie
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hqq9r147ifkola39td5spofe3s